SESSION 8: High Dose Lung Delivery:
Changing the Treatment Paradigm for Lung Diseases
Wednesday • May 8, 2024 • 3:30–5:00 PM • Arizona Ballroom
Moderator: Paul J. Atkins, Ph.D.
The Evolving Unmet Need for High Dose Inhaled Therapies in Orphan Lung Diseases
Thomas Hofmann
Aumapharma
Aumapharma
High Dose Pulmonary Delivery: Addressing the Biological and Technical Challenges
Anthony Hickey
Astartein
Astartein
Patient Focused Device Systems for High Payload Therapies
Hugh Smyth
The University of Texas at Austin
The University of Texas at Austin
Discover More
Practical Considerations for Development and Scale-up of Spray Dried Inhalation Powders
Alan Watts and Thomas Lund
Catalent
Catalent
A Modular Approach to Understand the Design Space of a Capsule-Based High-performance DPI
Anselm Ebert and Mirjam Kobler
H&T Presspart
H&T Presspart
Integrated Carrier-Based Formulation Development: Process and Performance Considerations
Beatriz Noriega Fernandes
Lonza
Lonza
Blending Optimization in Multi-Component DPI Formulations
Rebekka Spellerberg and Stefano Biserni
MEGGLE
MEGGLE
Aerodynamic Characteristics of Spiriva® Handihaler® at Simulated Breathing Patterns of COPD and Healthy Subjects, and at a Constant Inhalation Flow using One Capsule per Determination
Jufang Xu
CF PharmTech
CF PharmTech
Advancing DPI Technology: A Modular Approach on Optimizing Capsule Movement for Improved Performance
Mirjam Kobler
H&T Presspart
H&T Presspart
Ellipta® Blister Device: A Re-Assembly Set of Tools for Early In Vitro Comparative Studies of a Complex Pre-Metered Dry Powder Inhaler
Irene Rossi
Harro Höfliger
Harro Höfliger
Drug Load Influence on Aerodynamic Properties of High Dosage DPIs: A Case Study of an Aminoglycoside Model Drug
Maria Ines Lopes and Joao Pires
Hovione
Hovione
Understanding Leucine Encapsulation in Dry Powder Inhaler Microparticles via Surface Characterization Techniques
Lidia Santos and Claudia Costa
Hovione
Hovione
Novel Inhaled Anti-Viral Against SARS-CoV-2: Feasibility of Developing a Nanofitin Dry Powder Formulation for Pulmonary Delivery using the ICOone Single Dose Dry Powder Inhaler
Måns Österberg Widerstrand and Jakob Samsøe
Iconovo
Iconovo
Novel Insight into the Microstructure of Fines-Only Formulations using X-ray Computed Tomography with Machine Learning
Parmesh Gajjar and Darragh Murnane
InformiX Pharma
InformiX Pharma
Application of Raman Spectroscopy for Dry Powder Inhalation Formulation
Mridul Majumder
M2M Pharmaceuticals
M2M Pharmaceuticals
The Fluid Dynamics of a Dry Powder Inhaler Assisted with a Zero-Net-Mass-Flux Jet
Rina Perven
Monash University
Monash University
Impact of L-leucine on Stability and Aerosol Performance of Dry Powder Protein Formulations
Kinnari Arte
Purdue University
Purdue University
Physicochemical and Aerodynamic Stability of Spray Dried Tigecycline Inhalation Powder for the Treatment of Pulmonary Nontuberculous Mycobacterial Infections
Sara Maloney Norcross
RTI International
RTI International
The Anti-Microbial Peptide, H1b, for Non-Small Cell Lung Cancer Treatment: Dry Powder Formulation Development And Characterization
Alec Diorio and Alan Watts
St. John's University
St. John's University
Lipid-Based Spray Dried Microparticles of Monoclonal Antibodies for Inhalation
Varsha Nair and Rex Moore
The University of Texas at Austin
The University of Texas at Austin
A Comparison of the Aerosol Dispersion of Twelve Micronized Powders
Jamie Spahn
The University of Texas at Austin
The University of Texas at Austin
Effect of Flow Rate on Emitted Aerodynamic Particle Size Distribution from a Dry Powder Inhaler Delivering a Short-Acting Beta2 Agonist as Monotherapy
Mark Nagel
Trudell Medical International
Trudell Medical International
Characterizing Adasuve® (Loxapine, 10 mg) Inhalation Powder Particle Size Distribution Using Laser Diffraction
Nathan Reed
U.S. Food & Drug Administration
U.S. Food & Drug Administration
Characterization of Spray-Dried Phospholipid Porous Particles for Inhalation Drug Delivery
Susan Boc
U.S. Food & Drug Administration
U.S. Food & Drug Administration
The Use of Atomic Force Microscope-Infrared Spectroscopy to Assess Co-Localization of Fluticasone/Salmeterol/Lactose in Advair Diskus® 100/50 Formulations
Blessy Joseph
University of Alabama at Birmingham
University of Alabama at Birmingham
Optimization of Carbohydrate Excipient Ratios in Respirable Protein Powder Formulations
Grace Xia
University of Michigan
University of Michigan
Tailoring of a Pramlintide Pulmonary Dry Powder for Diabetes and Obesity Treatment
Francesca Buttini
University of Parma
University of Parma
Comparing Carbon Emissions for Three Dry Powder Inhaler Technologies
Francesca Buttini
University of Parma
University of Parma
Optical Photothermal Infrared Spectroscopic Assessment of Fluticasone/Salmeterol/Lactose Co-Association in Advair Diskus® and Wixela Inhub®
Dipesh Khanal
University of Sydney
University of Sydney
Comparison of In Vitro Aerosol Performance and Powder Characteristics of a Synthetic Lung Surfactant Powder Aerosol Formulation Produced using Two Spray Drying Methods
Felicia Hall
Virginia Commonwealth University
Virginia Commonwealth University
Spray Characterization of Low Volume Air-Jet Dry Powder Inhaler Devices for the Delivery of a Synthetic Lung Surfactant Powder Formulation
Caleb Dalton
Virginia Commonwealth University
Virginia Commonwealth University
Efficient Delivery of Powder Aerosol to the Lungs of Small Animals with a New Air-Jet Dry Powder Insufflator
Rudra Pangeni
Virginia Commonwealth University
Virginia Commonwealth University
In Vivo Efficacy of Tobramycin Excipient Enhanced Growth Dry Powder Aerosol in Pseudomonas Aeruginosa Lung Infection Model
Surendra Poudel
Virginia Commonwealth University
Virginia Commonwealth University
In Vitro Aerosol Delivery Performance of the Zenius Prototype Inhaler
Yui Muguruma
Zenius
Zenius
CONFERENCE SUPPORTERS
WORKSHOP PRESENTERS
EXHIBITORS
ORGANIZATIONS
Exhibitors
